Published by MyelinWatch:
MSC-NP / Tisch · Researchers studied neural precursor cells made from a person’s own bone-marrow cells and delivered into spinal fluid, with the aim of supporting repair in progressive MS.
Researchers turn a person’s own bone-marrow cells into neural precursor cells and deliver them into the spinal fluid. The intended strategy is to support repair or protection in progressive MS, potentially through signals released by the cells; the study does not establish that transplanted cells rebuild myelin in patients.
Approach source: Tisch Multiple Sclerosis Research Center — original MSC-NP article ↗
Researchers studied neural precursor cells made from a person’s own bone-marrow cells and delivered into spinal fluid, with the aim of supporting repair in progressive MS.
Phase 2 study evidence; current programme status is unknown
Current programme and human-study status are unknown.
A published analysis of two groups reported changes in spinal-fluid biomarkers. Those changes do not establish clinical benefit, and the current programme status is unknown.
This is an experimental cell approach, not an available treatment. The publication does not show that it improves symptoms or disability. The specific expanded-access pathway NCT03822858 is no longer available according to its registry record. This does not establish that the separate Phase 2 study NCT03355365 or the whole MSC-NP programme has closed; the overall programme status remains unknown.
A published analysis examined cerebrospinal-fluid samples from two groups of people with secondary or primary progressive MS: 50 participants in a Phase 2 study and 43 in an expanded-access programme. After repeated intrathecal autologous MSC-NP treatment, CCL2, MMP9, SCF and CHIT1 changed in cerebrospinal fluid. NfL and GFAP did not show the same pattern of change.
